EXEL vs TECH · P/E 17, rev $2.17B vs P/E 65, rev $1.22B
Exelixis Inc (EXEL) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Exelixis Inc (EXEL) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported EXEL revenue for 2025-01-03 was $2.17B. Net income was $521.3M. Revenue was up 18.5% from 2023-12-29 to 2025-01-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the EXEL and TECH stock pages for the full models.
Not investment advice.